JOURNAL BROWSE
Search
Advanced SearchSearch Tips
New Prognostic Scoring System for Incurable Stage IV Colorectal Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
New Prognostic Scoring System for Incurable Stage IV Colorectal Cancer
Kishiki, Tomokazu; Masaki, Tadahiko; Mastuoka, Hiroyoshi; Abe, Nobustugu; Mori, Toshiyuki; Sugiyama, Masanori;
  PDF(new window)
 Abstract
Background: Components of the systemic inflammatory response, combined to form inflammation-based prognostic scores (mGPS, NLR, PLR, PI, PNI) have been associated with overall survival. The aim of the present study was to compare various prognostic factors including many previously established parameters and such systemic inflammation-based prognostic scores in a series of incurable stage IV colorectal cancer (CRC) patients. Materials and Methods: Patients (n
 Keywords
Colorectal cancer;stage IV;GPS;CEA;
 Language
English
 Cited by
 References
1.
Baron JA, Sandler RS (2000). Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med, 51, 511-23. crossref(new window)

2.
Cho H, Hur HW, Kim SW, et al (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother, 58, 15-23. crossref(new window)

3.
Crumley AB, McMillan DC, Mckernan M, et al (2006). An elevated c-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer, 94, 1568-71.

4.
Crumley AB, McMillanDC, McKernan M, et al (2006). Evaluation of an inflammation-based prognostic score in patients with inoperable gastoro-oesophageal cancer. Br J Cancer, 94, 637-41.

5.
Daugherty SE, Pfeiffer RM, Sigurdson AJ, et al (2011). Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol, 173, 721-30. crossref(new window)

6.
García-Rodríguez LA, Huerta-Alvarez C (2001). Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiol, 12, 88-93. crossref(new window)

7.
Kanda M, Fujii T, Kodera Y, et al (2011). Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg, 98, 268-74. crossref(new window)

8.
Kao SC, Pavlakis N, Harvie R, et al (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res, 16, 5805-13. crossref(new window)

9.
Kasymjanova G, MacDonald N, Agulnik JS, et al (2010). The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol, 17, 52-8.

10.
Kishiki T, Masaki T, Matsuoka H, et al (2013). Modified glasgow prognostic score in patients with incurable stage IV colorectal cancer. Am J Surg, 206, 234-40. crossref(new window)

11.
Kobayashi T, Kawakami M, Kara Y, et al (2014). Combined evaluation of the Glasgow prognostic score and carcinoembryonic antigen concentration prior to hepatectomy predicts postoperative outcomes in patients with liver metastasis from colorectal cancer. Hepatogastroenterol, 133, 1359-62

12.
Langman MJ, Cheng KK, Gilman EA, et al (2000). Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ, 320, 1642-6. crossref(new window)

13.
McMillan DC, Crozier JE, Canna K, et al (2007). Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis, 22, 881-6. crossref(new window)

14.
Nozoe T, Kimura Y, Ishida M, et al (2002). Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol, 28, 396-400. crossref(new window)

15.
Nozoe T, Ninomiya M, Maeda T, et al (2010). Prognostic nutritional index: A tool to predict the biological aggressiveness of gastric carcinoma. Surg Today, 40, 440-3. crossref(new window)

16.
Proctor MJ, Morrison DS, Talwar D, et al (2011). A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer, 47, 2633-41. crossref(new window)

17.
Rosen SA, Buell JF, Yoshida A, et al (2000). Initial presentation with stage IV colorectal cancer: How aggressive should we be? Arch Surg, 4, 534-5.

18.
Sarraf KM, Belcher E, Raevsky E, et al (2009). Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg, 137, 425-8. crossref(new window)

19.
Schmoll HJ, Van Cutsem E, Stein A, et al (2012). ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol, 23, 2479-516. crossref(new window)

20.
Smith RA, Bosonnet L, Raraty M, et al (2009). Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg, 197, 466-72. crossref(new window)

21.
Walsh SR, Cook EJ, Goulder F, et al (2005). Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4. crossref(new window)